Axsome Therapeutics, Inc. last reported quarterly results on Nov 2, 2026, for Q3 FY2026 (the quarter ended Sep 30, 2026): revenue of $259.7 million (+51.9% year over year) and diluted EPS of -$0.25. It usually reports 12–41 days after a quarter ends. Based on that pattern, the next release is estimated for around Jan 11, 2027.
Results for Q4 FY2026, the quarter ending around Dec 31, 2026. Expected on a Monday. Based on last year's release for the same quarter on Jan 12, 2026. This is an estimate, not a date the company has announced.
Release dates are when the company filed its earnings announcement with the SEC (Form 8-K, Item 2.02); select a date to open the filing. It usually reports 12–41 days after a quarter ends. Figures are USD in millions, except EPS. The colored percent is the change from the same quarter a year earlier. Until a quarter's 10-Q or 10-K figures reach the SEC's data, they come from the earnings press release, and are shown only when its year-ago numbers match the filed ones. A dash means the figure could not be confirmed yet.
| Released | Quarter | Revenue | Net income | Diluted EPS |
|---|---|---|---|---|
|
Nov 2, 2026
33 days after quarter end
|
Q3 FY2026
ended Sep 30, 2026
|
260
+51.9%
|
-13
+72.7%
|
-0.25
+73.4%
|
|
Aug 10, 2026
41 days after quarter end
|
Q2 FY2026
ended Jun 30, 2026
|
218
+45.5%
|
-51
-7.0%
|
-0.99
-2.1%
|
|
May 4, 2026
34 days after quarter end
|
Q1 FY2026
ended Mar 31, 2026
|
191
+57.4%
|
-65
-8.6%
|
-1.26
-3.3%
|
|
Jan 12, 2026
12 days after quarter end
|
Q4 FY2025
ended Dec 31, 2025
|
196
+65.0%
|
-29
+61.9%
|
-0.56
+63.4%
|
|
Nov 3, 2025
34 days after quarter end
|
Q3 FY2025
ended Sep 30, 2025
|
171
+63.2%
|
-47
+26.9%
|
-0.94
+29.9%
|
|
Aug 4, 2025
35 days after quarter end
|
Q2 FY2025
ended Jun 30, 2025
|
150
+72.1%
|
-48
+39.5%
|
-0.97
+41.9%
|
|
May 5, 2025
35 days after quarter end
|
Q1 FY2025
ended Mar 31, 2025
|
121
+62.0%
|
-59
+13.1%
|
-1.22
+15.3%
|
|
Jan 13, 2025
13 days after quarter end
|
Q4 FY2024
ended Dec 31, 2024
|
119
+66.0%
|
-75
+24.1%
|
-1.54
+26.0%
|
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- AXSM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- New York, NY
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1579428
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.